Product image of Lenvatinib Remedica (Lenvatinib) supplied by GNH India

Lenvatinib Remedica

Active Ingredient:
Lenvatinib
Origin:
EU

Lenvatinib Remedica (Lenvatinib)

Lenvatinib, the active ingredient in Lenvatinib Remedica, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of certain advanced cancers, including radioiodine‑refractory differentiated thyroid cancer, hepatocellular carcinoma, renal cell carcinoma, and endometrial carcinoma, in adult patients whose disease has progressed despite prior therapy.

GNH India supplies Lenvatinib Remedica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Remedica Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lenvatinib is a targeted oral therapy used in several solid‑tumour indications where angiogenesis drives disease progression.

  • Radioiodine‑refractory differentiated thyroid cancer: helps control tumour growth and prolongs progression‑free survival.
  • Hepatocellular carcinoma: provides an anti‑angiogenic effect that can extend overall survival in patients not amenable to curative therapies.
  • Renal cell carcinoma: inhibits tumour vascularisation, improving disease control in advanced cases.
  • Endometrial carcinoma: used in combination with pembrolizumab to enhance anti‑tumour activity in advanced disease.

How It Works

  • Lenvatinib blocks multiple receptor tyrosine kinases—including VEGFR1‑3, FGFR1‑4, PDGFRα, KIT and RET—thereby suppressing angiogenesis and tumor cell proliferation. By inhibiting these pathways, the drug reduces blood‑vessel formation that supplies tumors and interferes with signaling that drives cancer cell growth and survival.

Side Effects

Lenvatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Hypertension: elevated blood pressure requiring monitoring and management.
  • Diarrhea: may be mild to moderate and manageable with supportive care.
  • Fatigue: persistent tiredness affecting daily activities.
  • Decreased appetite and nausea: gastrointestinal discomfort common during treatment.
  • Proteinuria: presence of protein in urine, indicating renal involvement.

Serious or Rare Side Effects

  • Hemorrhage: risk of severe bleeding, especially in patients with vascular lesions.
  • Arterial thromboembolic events: includes stroke or myocardial infarction.
  • Gastrointestinal perforation or fistula formation: rare but life‑threatening complications.
  • Hepatotoxicity: significant liver enzyme elevations requiring interruption of therapy.
  • Severe wound healing complications: delayed recovery after surgery or injury.

Precautions & Warnings

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly.

  • Blood pressure monitoring: check and control hypertension throughout treatment.
  • Liver function tests: evaluate hepatic enzymes before and during therapy.
  • Renal assessment: screen for proteinuria and adjust dosing if needed.
  • Wound healing: postpone treatment before major surgery and monitor post‑operative recovery.
  • Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Lenvatinib can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenvatinib exposure.
  • Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened risk of bleeding.
  • High‑dose aspirin or NSAIDs: can exacerbate hemorrhagic events.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug levels.
  • Antihypertensive agents: may require dose adjustments due to blood‑pressure effects.
  • Diuretics: monitor electrolytes and renal function when combined.

Frequently Asked Questions

Lenvatinib Remedica is an oral tyrosine kinase inhibitor indicated for adult patients with radioiodine‑refractory differentiated thyroid cancer, advanced hepatocellular carcinoma, metastatic renal cell carcinoma, and endometrial carcinoma that have progressed after prior therapy. It works by inhibiting pathways that promote tumor blood‑vessel formation and cell proliferation.

Lenvatinib blocks multiple receptor tyrosine kinases such as VEGFR1‑3, FGFR1‑4, PDGFRα, KIT and RET. By inhibiting these receptors, the drug reduces angiogenesis—the formation of new blood vessels that feed tumors—and interferes with signaling that drives cancer cell growth, leading to slowed disease progression.

The specific dose and schedule of Lenvatinib Remedica are determined by the prescribing physician based on the patient’s indication, disease stage, renal and hepatic function, and tolerance. Healthcare professionals adjust the regimen to achieve optimal therapeutic benefit while managing potential side effects.

Safety data for Lenvatinib in pregnancy and lactation are limited, and the drug may pose risks to the fetus or nursing infant. It is generally advised to avoid use during pregnancy and breastfeeding unless the potential benefit justifies the potential risk. Women of child‑bearing potential should use effective contraception.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Lenvatinib Remedica. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lenvatinib differs from agents such as sorafenib or sunitinib by targeting a broader spectrum of kinases, including FGFR1‑4 and RET, in addition to VEGFRs. This broader inhibition can translate into distinct efficacy profiles in certain cancers, but the safety and tolerability patterns also vary, requiring individualized assessment by the treating oncologist.

Lenvatinib Remedica should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity to maintain its stability.

Lenvatinib Remedica is taken orally, usually once daily, with or without food as directed by the prescriber. Patients should swallow the tablet whole with a full glass of water and follow any specific instructions regarding timing relative to meals or other medications.

The most serious adverse events include severe hypertension, hemorrhage, arterial thromboembolic events (such as stroke or heart attack), gastrointestinal perforation or fistula formation, and significant liver toxicity. Patients should be monitored closely for these conditions, and any concerning symptoms should prompt immediate medical evaluation.

Lenvatinib is contraindicated in patients with known hypersensitivity to lenvatinib or any of its excipients. Caution is advised for individuals with uncontrolled hypertension, recent major surgery, active bleeding disorders, or severe hepatic impairment. The drug should also be avoided in pregnant women and used only if the benefits outweigh the risks in breastfeeding mothers.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenvatinib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT